Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).
Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).
No indication information available.
No associated conditions information available.
Stay informed with timely notifications on clinical trials and research advancements.